IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of ...

“Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in the ...

"Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in ...

It is up to WRN to demonstrate they will build a world-class operation that is engineered and developed properly and with utmost care taken to mitigate any risks to the environment. Above-average ...

In addition, Eikon’s early-stage pipeline features two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its potential as a therapy for ...

Eikon’s early-stage pipeline houses two androgen receptor antagonists and a WRN inhibitor dubbed EIK1005, which is being studied for its potential as a therapy for patients with microsatellite ...

Eikon's early-stage pipeline features, among other undisclosed candidates, two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its ...